Description
Avatrombopag
EACH FILM-COATED LUCITRAM TABLET CONTAINS
Avatrombopag maleate 23.6mg equivalent to Avatrombopag 20mg
INDICATION
LuciAvat is a thrombopoietin receptor agonist indicated for the treatment of: • Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. • Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
DOSAGE AND USE
1) Chronic Liver Disease: Dose LuciAvat based upon platelet count prior to procedure, orally for 5 days beginning 10 to 13 days before procedure. For platelet count less than 40 × 10 /L, the dose is 60 mg (3 tablets) once daily; for platelet count 40 to less than 9 50 × 10 /L, the dose is 40 mg (2 tablets) once daily. 2) Chronic Immune Thrombocytopenia: Initiate LuciAvat at 20 mg (1 tablet) once daily. Adjust the dose or frequency of dosing to maintain platelet count greater than 9 or equal to 50 × 10 /L. Do not exceed 40 mg per day. Tablets should be swallowed whole & not chewed or crushed and with food.
STORAGE
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION
To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.
Reviews
There are no reviews yet.